Increased HIV Infection Linked to Pandemic-Related Access to PrEP

Kate Johnson

October 06, 2022

Changes to HIV preexposure prophylaxis (PrEP) access during the COVID-19 pandemic were linked to higher rates of HIV infection among young sexual minority men and gender-diverse individuals who identified as Black and/or Hispanic/Latino, according to a national survey.

"The public health crisis surrounding COVID-19 had clear impact on PrEP access and risk of HIV acquisition overall," said lead investigator Ethan Morgan, PhD, College of Nursing and the Infectious Disease Institute at The Ohio State University, in Columbus, Ohio.

"This is a stark lesson that when novel public health emergencies arise, extant ones cannot go by the wayside, or we risk exacerbating them, such as we see here," he told Medscape Medical News.

The online survey was administered in four waves during the first year and a half of the pandemic, starting in March 2020. Participants were recruited through mailing lists, national networks, community partners, and social media.

Among 796 baseline respondents, 300 agreed to three follow-up surveys administered between February and March 2021, between July and August 2021, and between October and November 2021.

Inclusion required participants to identify as Black and/or Hispanic/Latino, be between ages 18-29 years, be assigned male at birth, reside in the United States, and have reported anal intercourse with a man in the past 12 months. The researchers noted that given the limited uptake of and adherence to PrEP in the targeted population, they prioritized baseline respondents who reported either current PrEP use or use at least once in their lifetime.

The researchers used separate multivariable logistic regression models to assess the association between odds of testing positive for HIV and other sexually transmitted infections (STIs) across the four online study visits and (a) pandemic-related changes to PrEP access, and (b) pandemic-related changes to sexual activity.

Changes in PrEP access were reported by a total of 109 (13.8%) of baseline respondents, and HIV seroconversion was reported in 25 of 292 respondents (8.6%) who reported their HIV and other STI status at follow-up. STI positivity was reported 25.6% of the baseline cohort (n = 204).

Compared with respondents who reported no changes to PrEP access, those who did report change to access were significantly more likely to report HIV seroconversion (adjusted odds ratio [aOR], 2.80; 95% CI, 1.02-7.68). However, Morgan emphasized that the study question did not ask how PrEP had changed, only if it had.

"While we presume this survey question corresponds to a diminished access to PrEP medication during the COVID-19 pandemic, the question was, 'Has your access to PrEP been impacted by the COVID-19 pandemic?' So, it is unfortunately unclear whether access was diminished or improved," he explained. STI positivity was not associated with PrEP access.

The survey also asked respondents how much the pandemic had impacted their sexual activity (measured on a Likert scale of not at all, a little, moderately, quite a bit, and extremely). Respondents reporting greater impact on their sexual activity were more likely to report an STI (aOR, 1.24; 95% CI, 1.10-1.40) during the study period.

In addition, though participants reported a mean of 2.8 sexual partners in the past 3 months, those reporting a greater number were more likely to report an STI (aOR, 1.29; 95% CI, 1.21-1.38).

The researchers suggested that expansion of telehealth and mail-order prescriptions as well as structural-level interventions addressing pandemic-related unemployment and loss of health insurance could have helped preserve access to PrEP.

Commenting on the study, Monica Gandhi, MD, MPH, who was not involved in the research, noted that self-reported data can be subject to bias. "However, reduction in services for other medical care has been reported frequently throughout COVID and so this finding of reduced PrEP access, and subsequent HIV infection, is completely in line with the other studies," she told Medscape Medical News.

Gandhi, who is director of the University of California, San Francisco Center for AIDS Research and medical director of the HIV/AIDS Clinic ("Ward 86") at San Francisco General Hospital, added: "We knew early on in the COVID-19 pandemic that access to and uptake of PrEP was decreased based on data from Boston's Fenway Institute."

The Boston data, reported July 2020 at the virtual International AIDS Conference, prompted "a real attempt" by clinicians to increase PrEP access and uptake — raising community awareness, dispensing PrEP through mobile units, and changing prescribing patterns, Gandhi said. "We usually see patients every 3 months for PrEP but with HIV self-testing, we can extend that interval to every 6 months, and we did so in many centers during COVID."

The study was funded by National Institute on Drug Abuse, part of the National Institutes of Health.

Morgan and Gandhi reported no conflicts of interest.

J Acquir Immune Defic Syndr. Published online October 1, 2022. Abstract

Kate Johnson is a Montreal-based freelance medical journalist who has been writing for more than 30 years about all areas of medicine.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....